Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258334 | 0.90 | CA2 (0.50) | CA2CA1CA9CA12CA5A | |
| SCHEMBL1246000 | 0.86 | CYP4F2 (0.47) | CA2CA1CA9CA12CA4 | |
| Alcohol SCHEMBL4228476 | 0.84 | CA1 (0.41) | CA2CA1CA9TSHRKDM4E | |
| SCHEMBL6991225 | 0.82 | CA1 (0.48) | CA2CA1CA9CA12TSHR | |
| SCHEMBL17891745 | 0.82 | CA2 (0.44) | CA2CA1CA9TSHRKDM4E | |
| SCHEMBL13527822 | 0.82 | CA2 (0.50) | CA2CA1CA9TSHRKDM4E | |
| SCHEMBL3591170 | 0.81 | CA1 (0.41) | CA2CA1CA9CA12CA4 | |
| SCHEMBL3863603 | 0.81 | CA1 (0.43) | CA2CA1CA9TSHRKDM4E | |
| SCHEMBL980388 | 0.81 | CA1 (0.44) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1284072 | 0.81 | CA1 (0.43) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010067102-A1 | DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067102-A1 | DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CA2 1251/4885CA1 2579/4885CA9 1651/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CA2 1251/4885CA1 2579/4885CA9 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.